The FLAURA study compared first-line osimertinib versus geftitinib or erlotinib and demonstrated
The FLAURA study compared first-line osimertinib versus geftitinib or erlotinib and demonstrated
Cancer MCQs
Which of the following is the most common cause of acquired resistance to EGFR TKI therapy?
Which of the following is the most common cause of acquired resistance to EGFR TKI therapy?
Which of the following is not a second generation EGFR TKI used in NSCLC?
Which of the following is not a second generation EGFR TKI used in NSCLC?
Which of the following is not a second generation EGFR TKI used in NSCLC? Read More »
Which of the following is true regarding EGFR mutations?
Which of the following is true regarding EGFR mutations?
Which of the following is true regarding EGFR mutations? Read More »
Based on the results of IMPRESS trail in NSCLC, which of the following is true :
Based on the results of IMPRESS trail in NSCLC, which of the following is true :
Based on the results of IMPRESS trail in NSCLC, which of the following is true : Read More »
Which of the following mutation is not routinely tested in lung cancer patients?
Which of the following mutation is not routinely tested in lung cancer patients?
Which of the following mutation is not routinely tested in lung cancer patients? Read More »
Molecular testing on tumor specimens should be performed on which of the following advanced squamous lung cancer subsets
Molecular testing on tumor specimens should be performed on which of the following advanced squamous lung cancer subsets
Cytotoxic chemotherapy will not be recommended in which of the following performance status of a patient with NSCLC
Cytotoxic chemotherapy will not be recommended in which of the following performance status of a patient with NSCLC
If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach
If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach
Which of the following is not true regarding the immune checkpoint inhibitor durvalumab?
Which of the following is not true regarding the immune checkpoint inhibitor durvalumab?
Which of the following is not true regarding the immune checkpoint inhibitor durvalumab? Read More »